I Doycheva1, J Cui1, P Nguyen1,2, E A Costa3, J Hooker3, H Hofflich4, R Bettencourt5, S Brouha6, C B Sirlin3, R Loomba1,2,5. 1. NAFLD Translational Research Unit, Department of Medicine, University of California, San Diego, La Jolla, CA, USA. 2. Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA. 3. Liver Imaging Group, Department of Radiology, University of California, San Diego, La Jolla, CA, USA. 4. Division of General Internal Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA, USA. 5. Division of Epidemiology, Department of Family and Preventive Medicine, University of California, San Diego, La Jolla, CA, USA. 6. Department of Radiology, University of California, San Diego, La Jolla, CA, USA.
Abstract
BACKGROUND: Current guidelines do not recommend screening for non-alcoholic fatty liver disease (NAFLD) or advanced fibrosis. Patients with type 2 diabetes mellitus (T2DM) are known to be at increased risk for NAFLD and advanced fibrosis. AIM: To assess the feasibility in diabetics in a primary care setting of screening for NAFLD and advanced fibrosis, by using non-invasive magnetic resonance imaging (MRI) to estimate the hepatic proton density fat fraction (MRI-PDFF) and magnetic resonance elastography (MRE) to estimate hepatic stiffness. METHODS: We performed a cross-sectional analysis of a prospective study that included 100 (53% men) consecutively enrolled diabetics who did not have any other aetiology of liver disease. All patients underwent a standardised research visit, laboratory tests, MRI-PDFF, and MRE. RESULTS: Mean (±s.d.) age and body mass index (BMI) was 59.7 (±11.2) years and 30.8 (±6.5) kg/m(2) , respectively. The prevalence of NAFLD (defined as MRI-PDFF ≥5%) and advanced fibrosis (defined as MRE ≥3.6 kPa) was 65% and 7.1%, respectively. One patient with advanced fibrosis had definite hepatocellular carcinoma. When compared to those without NAFLD, patients with NAFLD were younger (P = 0.028) and had higher mean BMI (P = 0.0008), waist circumference (P < 0.0001) and prevalence of metabolic syndrome (84.6% vs. 40.0%, P < 0.0001). Only 26% of those with NAFLD had elevated alanine aminotransferase. CONCLUSIONS: This proof-of-concept study demonstrates that T2DM has significant rates of both NAFLD and advanced fibrosis. Concomitant screening for NAFLD and advanced fibrosis by using MRI-proton density fat fraction and magnetic resonance elastography in T2DM is feasible and may be considered after validation in a larger cohort.
BACKGROUND: Current guidelines do not recommend screening for non-alcoholic fatty liver disease (NAFLD) or advanced fibrosis. Patients with type 2 diabetes mellitus (T2DM) are known to be at increased risk for NAFLD and advanced fibrosis. AIM: To assess the feasibility in diabetics in a primary care setting of screening for NAFLD and advanced fibrosis, by using non-invasive magnetic resonance imaging (MRI) to estimate the hepatic proton density fat fraction (MRI-PDFF) and magnetic resonance elastography (MRE) to estimate hepatic stiffness. METHODS: We performed a cross-sectional analysis of a prospective study that included 100 (53% men) consecutively enrolled diabetics who did not have any other aetiology of liver disease. All patients underwent a standardised research visit, laboratory tests, MRI-PDFF, and MRE. RESULTS: Mean (±s.d.) age and body mass index (BMI) was 59.7 (±11.2) years and 30.8 (±6.5) kg/m(2) , respectively. The prevalence of NAFLD (defined as MRI-PDFF ≥5%) and advanced fibrosis (defined as MRE ≥3.6 kPa) was 65% and 7.1%, respectively. One patient with advanced fibrosis had definite hepatocellular carcinoma. When compared to those without NAFLD, patients with NAFLD were younger (P = 0.028) and had higher mean BMI (P = 0.0008), waist circumference (P < 0.0001) and prevalence of metabolic syndrome (84.6% vs. 40.0%, P < 0.0001). Only 26% of those with NAFLD had elevated alanine aminotransferase. CONCLUSIONS: This proof-of-concept study demonstrates that T2DM has significant rates of both NAFLD and advanced fibrosis. Concomitant screening for NAFLD and advanced fibrosis by using MRI-proton density fat fraction and magnetic resonance elastography in T2DM is feasible and may be considered after validation in a larger cohort.
Authors: Z Permutt; T-A Le; M R Peterson; E Seki; D A Brenner; C Sirlin; R Loomba Journal: Aliment Pharmacol Ther Date: 2012-05-03 Impact factor: 8.171
Authors: Mariana Lazo; Ruben Hernaez; Mark S Eberhardt; Susanne Bonekamp; Ihab Kamel; Eliseo Guallar; Ayman Koteish; Frederick L Brancati; Jeanne M Clark Journal: Am J Epidemiol Date: 2013-05-23 Impact factor: 4.897
Authors: Mazen Noureddin; Jessica Lam; Michael R Peterson; Michael Middleton; Gavin Hamilton; Thuy-Anh Le; Ricki Bettencourt; Chris Changchien; David A Brenner; Claude Sirlin; Rohit Loomba Journal: Hepatology Date: 2013-10-17 Impact factor: 17.425
Authors: R Kwok; Y-K Tse; G L-H Wong; Y Ha; A U Lee; M C Ngu; H L-Y Chan; V W-S Wong Journal: Aliment Pharmacol Ther Date: 2013-12-05 Impact factor: 8.171
Authors: Lindsey M Negrete; Michael S Middleton; Lisa Clark; Tanya Wolfson; Anthony C Gamst; Jessica Lam; Chris Changchien; Ivan M Deyoung-Dominguez; Gavin Hamilton; Rohit Loomba; Jeffrey Schwimmer; Claude B Sirlin Journal: J Magn Reson Imaging Date: 2013-10-17 Impact factor: 4.813
Authors: Cheng William Hong; Gavin Hamilton; Catherine Hooker; Charlie C Park; Calvin Andrew Tran; Walter C Henderson; Jonathan C Hooker; Soudabeh Fazeli Dehkordy; Jeffrey B Schwimmer; Scott B Reeder; Claude B Sirlin Journal: Abdom Radiol (NY) Date: 2019-10